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2Abstract
Initiator-free injectable hydrogels are very interesting for drug and/or cell delivery applications, since 
they can be administered in a minimally invasive way, without recurring to chemical initiators that 
could be harmful. In the current work, oxidized dextran crosslinked (dexOx) with adipic acid 
dihydrazide (AAD) hydrogels were further characterized and tuned to produce formulations, having in 
sight an injectable ocular formulation for the possible treatment of posterior eye diseases. The gelation 
rate and the hydrogels dissolution profile were shown to be dependent on the balance between the 
dextran oxidation degree, and both components concentration. On the in vitro studies, rabbit corneal 
endothelial cells were seeded on the hydrogels, to assess cytotoxicity. Hydrogels prepared with low 
oxidized dextrans were able to promote cell adhesion and proliferation to confluence in just 24 hours, 
while higher oxidized samples promoted cell adhesion and proliferation, but without achieving 
confluence. Cell viability studies were performed using MTS assays to verify the non-cytotoxicity of 
hydrogels and their degradation byproducts, rendering these formulations attractive for further in vivo
studies.
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31. Introduction
Ocular diseases of the posterior eye segment are the most common cause of visual disorders in 
industrialized countries1. These illnesses include, for example, cataracts, diabetic retinopathy, macular 
degeneration associated with aging and retinitis pigmentosa1,2. The visual disorders cause discomfort, 
anxiety and fear of losing the vision in patients.
Until now, ocular drug market is dominated by drugs, which were conceived to treat illnesses that 
affect the anterior eye segment, such medicines include:  antibiotics, anti-inflammatory agents or anti-
glaucoma drugs, usually as eye drop formulations1,3. These topical applications, in the form of eye 
drops, are ineffective in many cases, due mainly to the drainage system of the eye, which leads to poor 
ocular bioavailability4. New drugs have been developed to reach the posterior eye segment, although, 
most of them are administered through repeated intravitreal injections. This method is associated with 
complications such as pain, increased intraocular pressure, retinal detachment and endophtalmitis 
(which may lead to blindness). New methods of drug delivery, more secure, efficient, comfortable and 
with prolonged activity are needed, to minimize the number of injections. Currently, there are systems 
of controlled drug delivery on the market or being tested, such as implants, hydrogels and colloids1.
Hydrogels are hydrophilic polymer networks, which may absorb up to thousands of times their dry 
weight in water. Hydrogels may be chemically stable or they may degrade and eventually disintegrate 
and dissolve. They are called “reversible” or “physical” gels when the networks are held together by 
molecular entanglements, and/or secondary forces including ionic, H-bonding or hydrophobic forces. 
Hydrogels are called “permanent” or “chemical” gels when they are covalently-crosslinked networks5.
Recently, Van Tomme and collaborators compiled the different strategies used in producing 
dextran-based hydrogels, demonstrating dextran as a very versatile starting polymer for hydrogel 
synthesis6. Furthermore, pharmaceuticals and various potential therapeutic agents can easily be 
incorporated and its release profile controlled. Recently, human embryonic stem-cell encapsulation 
was also successfully achieved in bioactive hydrogels of dextran-acrylate7.
4Dextran is biocompatible and can be degraded through the action of dextranases in various organs in 
the human body, including liver, spleen, kidney and colon8.
Dextran oxidation by sodium periodate is an easy and well-known way to functionalize dextran with 
aldehyde moieties9. This chemical functionality has been widely tested to conjugate N-nucleophiles, 
due to their fast and almost complete reaction10. This approach has been tested on the synthesis of pro-
drugs11, as a spacer in enzyme immobilization12 or for growth factor controlled release13. On the 
preparation of hydrogels, different aminated crosslinkers, like chitosan14,15, gelatin16, 8-arm PEG 
amine17 or polyhydrazides18 have been used to yield chemical initiator-free formulations.
Recently, we described an injectable formulation composed of oxidized dextran (dexOx) crosslinked 
with adipic acid dihydrazide (AAD) 19. The dexOx with 15% oxidation degree (OD) was crosslinked 
with AAD, forming a gel within 2–4 minutes, depending on the AAD concentration used. The 
obtained hydrogels were characterized by their mechanical properties (7 – 32 kPa), swelling and 
degradation (9 to 23 days) behavior under physiologic conditions.
In this work, oxidized dextran, with various OD, was studied in order to improve the control of the 
system properties. The influence of dextran OD and concentration in the solution viscosity was 
monitored. We observed that the hydrogel swelling and dissolution could also be controlled by the 
dextran oxidation degree and that the dissolution profile could be extended for more than 2 months, 
improving the previous studied formulation. Cell toxicity assays were carried out in 96-well plates 
with different dexOx’s hydrogels. Cell viability studies were performed using rabbit corneal 
endothelial cells, which were seeded on top of the dexOx’s hydrogels. The cell adhesion and growth 
was visualized by optical microscopy and dehydrogenase activity of cells was evaluated by reduction 
of the MTS reagent.
2. Experimental Section 
52.1. Materials
Dextran (from Leuconostoc mesenteroides; Mw 60'000 Da, according to Fluka's specification), 
sodium periodate, adipic acid dihydrazide, tert-butyl carbazate (tBC), ethyl carbazate (EtC), phosphate 
buffered saline (PBS), dialysis tubes (MWCO ~12'000 Da), amphotericin B, L-glutamine, Minimum 
Essential Medium Eagle, penicillin G, streptomycin, and trypsin were purchased from Sigma (Sintra, 
Portugal). Foetal bovine serum was purchased from Biochrom AG (Berlin, Germany). The 3-[4,5-
dimethylthiazol-2-yl]-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt 
(MTS) and electron coupling reagent (phenazine methosulfate; PMS) were purchased from Promega.
T-flasks and 96 well plates were purchased from Nunc (Denmark).
2.2. Dextran oxidation
An aqueous solution of dextran (1 g; 0.125%, w/v) was oxidized with 2 mL of sodium periodate 
solution with different concentrations (33 – 264 mg/mL) to yield theoretical oxidations from 5 to 40%, 
at room temperature. The reaction was stopped after 4 hours. The resulting solution was dialyzed for 3 
days against water, using a dialysis tube with a MWCO 12-14,000 Da, and then lyophilized (Snidjers 
Scientific type 2040, Tillburg, Holland). The scale-up of the reaction was done using the same 
procedure albeit using 30 g of dextran and a calculated amount of periodate to yield a theoretical 
oxidation of 5, 10, 25 and 40%.
2.3. Nuclear magnetic resonance (NMR) and size exclusion chromatography (SEC)
The OD of dexOx is defined as the number of oxidized residues per 100 glucose residues (OD refers 
to the theoretical value unless otherwise stated) and quantified by using tBC20,21 and EtC. The 
carbazates react with aldehyde groups to form carbazones in the same way hydrazones are formed in 
the presence of hydrazides.
1H spectra were acquired on a Varian 600 NMR spectrometer (Palo Alto, CA) using a 3 mm 
broadband NMR probe. 1H NMR spectra were recorded in D2O (20-25 mg in 0.2 mL; pD of ca. 5.0) 
6using a 90º pulse and a relaxation delay of 30 s. The water signal, used as reference liQHZDVVHWDWį
4.75 ppm and was partially suppressed by irradiation during the relaxation delay. A total of 32 scans 
were acquired for each 1H NMR spectra. The spectra were analyzed with iNMR software, version 
2.6.4 (www.inmr.net).
Size exclusion chromatography was performed in a HPLC system composed of a degasser and a 
WellChrom Maxi-Star k-1000 pump (Knauer), coupled to a LS detector (evaporative light scattering 
PL-EMD 960) and one column (PL aquagel-OH Mixed 8 !m) from Polymer Laboratories. The whole 
system was kept at room temperature and the eluent used was KNO3 (0.001 M; pH 3.9) at a flow rate 
of 0.4 mL/min. Samples and standards were dissolved in the eluent at 4-6 mg/mL (Fluka Chemie AG, 
dextran standards from 12 – 80 kDa).
2.4. DexOx’s solutions viscosity
Dextran and dexOx’s solutions, with concentrations ranging from 10 to 30% (w/w) in PBS, were
prepared and analyzed in a Brookfield Programmable D-II+ Viscometer with a S18 spindle, assisted 
by DVLoader v1.0 software. The chamber temperature was controlled by an external bath to 25 ºC, 
and the chamber was loaded with 8 mL of solution.
2.5. Hydrogel preparation and characterization
The several oxidized dextrans were dissolved in different concentrations; dexOx 5% (D5) and 10% 
(D10) solutions were used at 30% (w/w) and dexOx 25% (D25) at 20% (w/w), in aqueous solvent 
(PBS) at 37 ºC until a liquid solution was obtained and then kept at 5 to 8 ºC, until further use. Then, 
250 !L of a given dexOx solution was mixed with 250 !L of a given AAD solution on homemade 
Teflon® molds and let to crosslink never less than 2 hours (except for the D5 hydrogels, which were 
let to cure over night). The AAD concentrations used are calculated based on a given molar percentage 
of dextran residues. The hydrogels nomenclature is as follows: dexOx 5% + AAD 5% - D5A5; and so 
forth.
72.6. Dynamic swelling experiments
DexOx hydrogels, after being prepared and weighted (Wi), were immersed in PBS (ca. 5 mL) in 6-
wells cell culture plates, at 37 ºC. At regular time intervals, they were removed from the aqueous 
solution, blotted in filter paper, weighted (Wt) and returned to the original well while PBS was 
replaced. 
Swelling Index: SI  Wt
Wi
(1)
2.7. Rheological analysis
Rheological experiments were carried out using the parallel plate geometry (20 mm diameter, steel) 
of a Haake Rheostress RS 1. On the calculation of gelation period, both solutions (190 !L each) were 
mixed on the bottom plate, and the upper plate was positioned at a gap of 1 mm (after gap 
optimization). This procedure took around 20 seconds after which the experiment was started at low 
frequency (0.5 Hz) and stress (0.1 Pa), to avoid interference with the network formation. The gelation 
rate was followed and the gelation period was considered to be the crossover point between G’ and 
G’’ (G’=G’’).
2.8. Cell source and growth
Corneal endothelial cells from rabbit were obtained as previously described22. Subsequently, cells 
were platted in T-flasks of 25 cm3 with Minimum Essential Medium Eagle (MEM) with heat-
inactivated foetal bovine serum (FBS, 10% v/v) and growth factors to do primary culture in agreement 
with the procedures previously described in the literature23. T-flasks with cells were incubated in a 5% 
carbon dioxide humidified atmosphere at 37ºC. On day 3, the medium was changed and here after 
every three days. Six days after cells attained confluence. 
After confluence was obtained, cells were sub-cultivated using 5 min incubation in 0.18 % trypsin 
(1:250) and 5 mM EDTA. The free cells were added to an equal volume of culture medium. Following 
8centrifugation, cells were resuspended in sufficient culture medium and seed in 96 well plates 
containing the biomaterials.
2.9. Cell culture and in vitro cytotoxicity studies
Two crosslinking degrees of AAD for each dexOx were selected and used on cytocompatibility 
tests. The oxidized dextran samples and AAD were either dissolved in PBS or in the appropriate cell 
culture medium, MEM.
Each formulation in the form of hydrogel was introduced (n=6), on wells of 96-wells cell culture 
plates, never exceeding 60 !L. The plates were irradiated for 30 minutes with UV, before being 
seeded with cells.
Forth passage endothelial corneal cells were seeded, at a density of 90’000 cells per well, into a 96-
well plate containing the hydrogels. The plate was incubated at 37ºC, under a CO2 (5%) humidified 
atmosphere. After 1, 3 and 7 days, cell viability was assessed through MTS assays. A CellTiter 96® 
AQueous Assay composed of 3-[4,5-dimethylthiazol-2-yl]-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) and an electron coupling reagent (phenazine 
methosulfate; PMS) from Promega were used. 20 !l of MTS/PMS were added to each sample and 
incubated for 4 h at 37ºC, under a CO2 (5%) atmosphere. The absorbance of the samples was 
determined at 492 nm using a Biorad Microplate Reader Benchmark.
Wells containing cells in culture medium without biomaterials were used as negative control (K-). 
Ethanol 96% was added to wells containing both types of cells to have a positive control (K+). The 
samples were analysed using an Olympus CX41 optical microscope equipped with an Olympus SP-
500 UZ digital camera.
3. Results and Discussion 
3.1. DexOx characterization
9Following previous work19, we characterized hydrogels made from dexOx with a wider range of 
oxidation degrees, crosslinked with different amounts of AAD. Dextran was oxidized by using sodium 
periodate at different percentages and characterized by 1H-NMR. The oxidation degree was not 
estimated by the TNBS assay, due to the good correlation of the NMR titration with the colorimetric 
assay, as shown in previous work19. The tert-butyl carbazate titration, however, causes sample 
precipitation when reacted with high oxidation degree samples, not allowing NMR spectra acquisition 
(D40, Table 1). We suggest that this effect is caused by the large tert-butyl moiety and we 
hypothesized that a less bulky molecule, such as ethyl carbazate, would not cause sample precipitation. 
In fact, both spectra are similar except for the ethyl protons peak which is sharper and slightly shifted 
upfield in comparison to the tert-butyl peak (spectra not shown). The real oxidation degree was 
calculated by taking into account the ratio between the integral of the peak at G 7.3 ppm (arising from 
the carbazone group formed either with tBC or EtC) and the integral of the anomeric proton at G 4.9 
ppm. The oxidation degrees obtained with EtC were slightly higher (Table 1) than that obtained with 
tBC titration, which may suggest some difficulty of tBC to react further due to its bulkier moiety.  
The dexOx number-average molecular weight (Mn), estimated by a SEC analysis, showed a clear 
decrease with increasing oxidation degree, but also an increasing polidispersity index (PDI), reflecting 
the higher range of dexOx molecular weights (Table 1).
3.2. DexOx solutions viscosity
On the design of injectable hydrogel formulations, details, like viscosity characterization, become 
increasingly important, in order to choose the best syringe geometries and/or needle gauges. Generally, 
the hydrogel characteristics can be tailored by the feed concentration14, degree of polymer 
modification and in other cases, chemical initiators concentration24. This particular system involves 
the mixing of two equal-volume solutions, each of which, with its own reactive species, oxidized 
dextran residues and the dihydrazide. Thus, the formulations design has to take into account the feed 
concentration halving, of both solutions, after mixing.
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Every dexOx sample, at any of the concentrations tested, showed a linear shear stress increase 
regarding the different shear rates, hence, a Newtonian behavior. For every concentration tested, across 
the different OD’s, the obtained viscosities for each dexOx series show a natural trend directly related 
with the concentration, as can be observed on Figure 2A for dextran and D40. The OD influence on 
viscosity seems to have a higher effect, when the polymer concentration is high, but as the polymer 
solution is less concentrated, the viscosity tends to decrease and eventually be lower than the reference 
solution (original dextran). 
Within the same concentration range, only the D25 viscosity falls below the dextran viscosity, but 
on the other hand, D40 has an extremely high viscosity reflecting the influence of the high reactivity, 
due to the high OD (Figure 2B).
We suggest that this effect is due to the molecular weight decrease with oxidation, which, below a 
certain concentration, counter-balances the crosslinking via hemiacetals (Figure 1A), decreasing the 
solution viscosity (Figure 2A), which could possibly be further enhanced by a dexOx chain coil due to 
the intra hemiacetal formation (Figure 1B), demonstrating how both parameters (OD and Mw) can 
interfere on the viscosity of a given dexOx solution.
3.3. Hydrogels characterization
The hydrogels preparation took into consideration three factors: the dexOx concentration/oxidation
degree and the AAD concentration. The first two are closely related due to the viscosity issues that 
were discussed above. Therefore, the concentration used was as high as the viscosity would allow it. 
Solutions of D5 and D10 with 30% concentration allow a good homogenization, despite the high 
viscosity, but for D25, we had to use a 20% concentration. The D40 macromonomer was not studied 
in deep detail as the others, due to its high reactivity for the concentration range wanted. The D40 with 
a 20% concentration yields a very viscous solution that reacts promptly with AAD, impairing a good 
homogenization. Lower concentrations produce nicer hydrogels, however with less attractive and more 
unpredictable swelling profiles. Yet, the D40 gelation rate data is presented (15% feed concentration), 
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to strengthen the issue on the balance between OD and AAD feed concentration effect on the gelation 
rate, discussed below.
The balance between the available crosslinking points (oxidation degree) and the amount of 
crosslinker used (AAD feed concentration) clearly affects the gelation rate, as shown on Table 2, 
however, not always on the same direction. The gelation periods of D25 and D40 hydrogels decrease 
with the AAD increase, while for the D5 and D10 hydrogels, the gelation periods increase directly 
with the AAD concentration. When low OD’s are present, the excess AAD increases the number of 
non-valid crosslinks, caused by the reaction of a single hydrazide, leaving a dangling end25, and 
retarding the hydrogel formation. The polymer feed concentration also affects the gelation periods, as 
can be observed with the D40 hydrogels, which should be faster than the D25, for the same AAD feed 
concentrations.
The dexOx/AAD hydrogels were prepared in Teflon molds and let to cure for at least two hours, 
except for the D5 hydrogels, which were left overnight, due to the slow curing rate. Equal volumes of 
dexOx and AAD solutions were added and mixed vigorously with the pipette tip, to achieve a good 
homogenization of both solutions. 
The hydrazide groups in AAD react with the aldehyde groups in oxidized dextrans forming 
hydrazone bonds, which are hydrolysable, retrieving the same chemical groups (Figure 1C), therefore, 
making these hydrogels soluble in different time frames. The swelling index (Equation 1) of the 
different sets of hydrogels showed how the dissolution profiles could be controlled, not only by the 
AAD amount but as well by the dextran OD. By increasing the OD, we can significantly increase the 
dissolution time of the hydrogels. This oxidation increase, allows that more AAD can be used as a 
crosslinking agent, reflecting on more lasting hydrogels. By balancing these two variables it is possible 
to control the dissolution profile of the hydrogels. 
As shown, low oxidation degrees do not allow long dissolution times. However, it is perfectly 
possible to control the dissolution profile with the AAD concentration, within a range of 5 days (Box 
in Figure 3). Rising up the oxidation, hydrogels more resistant to dissolution are obtained. The D25 
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hydrogels have very interesting profiles (Figure 3). The dissolution time could be extended up to 70 
days. Furthermore, one can observe an interesting plateau, with 20% AAD, resembling a saddle, 
approximately from the 2nd until the 50th day of immersion on phosphate buffer. Within this period the 
hydrogels maintained their size and shape without abrupt swelling variations. This profile seems to be 
interesting for the proposed application, as it will not swell above the injected volume and takes few 
weeks to dissolve. Just before the hydrogel collapses and dissolve, a maximum swelling peak is 
observed. We hypothesize this peak to be a fracture point, reached when the osmotic force equals the 
polymeric matrix force, which weakens through time, due to the AAD diffusion out of the hydrogel.  
The water content of the vitreous humour is around 98%, mainly composed of collagen, hyaluronic 
acid26 and hyalocytes of Balazs, which take care of removing cellular debris and reprocessing the 
hyaluronic acid27. Since the dexOx hydrogels are soluble in water and electrolyte solutions we think 
that the vitreous humour will naturally contribute to the dissolution of the hydrogel and help the 
hydrogel elimination. The by products of the designed hydrogel are its same initial components. 
Oxidized dextran and AAD. Both by-products should be excreted, to the aqueous humor, by the 
anterior route. This elimination is probably faster than through the blood-retina barrier to the systemic 
circulation1, despite that dextrans, up to 150 kDa, are diffusible through the sclera28.
3.4. Assessment of Cytotoxic Potential. 
The characteristics of these formulations render them suitable as a drug carrier to the posterior part 
of the eye, due to its injectable character, the controlled gelation rate or the dissolution profile shown. 
Formulations composed partially by dexOx have been tested for their biocompatibility. Recently, 
Bhatia and co-workers17, seeded 3T3 fibroblast cells on top of oxidized dextran (20% – 50% OD)
crosslinked with 8-arm PEG amine and showed that their formulation, was non-toxic and could lead to 
cell confluence after 24 hours of growth. This suggests, that the crosslinked-oxidized dextran can 
promote better cell adhesion than dextran itself29, despite showing some toxicity when present, alone, 
in cell culture with mesothelial cells30. 
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In the present work, endothelial cells from rabbit cornea were chosen based on the need to assess the 
oxidized dextran AAD crosslinked hydrogels cytotoxicity for the proposed application.
To assess the cytotoxicity of these materials, several combinations of hydrogels involving the 
different dexOx’s and AAD concentrations, were prepared. The 96-well cell culture plates were 
covered with 60 !L of hydrogels or just controls and the cells were seeded on top, after an over-night 
curing period. The materials used were not only dissolved in PBS but also on the appropriate cell 
culture media. Occasionally, the initial dexOx feed concentration had to be slightly decreased, due to 
the high viscosity, probably due to medium proteins, that crosslink with the oxidized dextran through 
the existing amine groups.
After cell seeding on top of the hydrogels, each well was visualized in optical microscope, to 
observe whether there was any cell adhesion and/or proliferation. Cells grew in the presence of all 
hydrogels tested, although cell growth, in the presence of D25 hydrogels, did not achieve confluence 
during the period of study (Figure 4).
Dextran is neutrally charged and we expect dexOx to keep the neutrality, as the periodate oxidation 
reaction does not yield any charged chemical groups. However, the crosslinking of dexOx with AAD 
(pKa 2.5) yields hydrazone bonds which were reported to have a pKa in the order of 3 to 431. Hence, 
due to the nature of the crosslinking bond, we suggest that the hydrogels zeta potential shifts 
negatively, allowing cell growth and proliferation.
It is well known that the surface chemistry of hydrogels can affect cell adhesion, proliferation and 
other phenomena. Chen et al32 work showed how the polymer nature and crosslinker concentration can 
dictate the surface charge density of the gels and strongly influence the cell behaviour. They have 
identified a threshold on the surface zeta potential (- 20 mV), below which cell adhere and proliferate.
Schneider and collaborators also reported that charge density of the hydrogel can regulate cell 
attachment either directly in the absence of extracellular matrix components, or indirectly through the 
association of extracellular matrix proteins found within the serum associated with charges of the 
hydrogel surface33.
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The MTS assay is a quick effective method for testing mitochondrial impairment and correlates 
quite well with cell proliferation. In recent years, it has been frequently used as a preliminary screen 
for the evaluation of in vitro cytotoxicity of polymeric components. 
The MTS assays were performed at 1, 3 and 7 days after cells being seeded on top of the hydrogels. 
Cellular activity did not seem to be affected by the medium used to prepare the hydrogels (MEM or 
PBS). The results (Figure 5) emphasize that every formulation promoted dehydrogenase activity. In 
the first 24 hours, all hydrogels promoted higher enzyme activity than the negative control. By the 3rd
day, the activity doubled for most hydrogels, with a few exceptions, and by the 7th day, the activity 
maintained the same levels. These results demonstrate the tested formulations as non-cytotoxic. 
4. Conclusions
On the estimation of the dextran oxidation degree, we have identified ethyl carbazate as a better and 
more accurate titrant, than tert-butyl carbazate, especially for the higher oxidized samples. The bulkier 
tBC moiety causes sample precipitation and it also seems to impair good access to the oxidized 
residues lowering the measured oxidation degree.
The viscosity studies revealed how the dextran oxidation degree can limit the concentration used. 
However, for diluted dexOx solutions, the lower molecular weight, counter-balances the oxidation 
effect, decreasing the viscosity.
The characterized hydrogels have a dual crosslinking control method, which lies on the dextran OD
and the amount of AAD used. The OD allows a given percentage of residues to serve as reactive 
points to molecules such as AAD. The amount of AAD used is crucial in defining the gelation period, 
mechanical properties and dissolution profile of the hydrogels. It should be within the same range of 
the amount of oxidized residues present in dextran, to avoid forming dangling ends, and not valid 
mechanical crosslinks.
On the cytotoxicity assay, the different dextran oxidation degrees tested were successful in 
promoting cell adhesion and growth. However, with the increasing oxidation, the cells took longer to 
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proliferate in the hydrogels. Oddly, the metabolic activity, measured by the MTS assay, showed very 
high levels of activity for the higher oxidized hydrogels, not corresponding to the cellular proliferation 
observed.
The proposed and studied system aims at providing a sustainable drug delivery device to the 
posterior part of the eye, which requires a single injection, but does not require further surgery on the 
removal of the device. The designed formulation is expected to dissolve and be eliminated naturally by 
the organism.
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Figure Captions
Figure 1 - The reactive aldehyde groups formed upon periodate oxidation are prone to establish inter 
(A) or intra (B) hemiacetals, when reacting with hydroxyl groups from nearby residues. The addition 
of AAD (C) promotes the reversible crosslinking with the formation of hydrazones.
Figure 2 – Shear stress versus Shear rate. (A) – Dextran with concentrations (w/w) of:  - 30%, { -
20%, U - 15% and  - 10%; and D40 with concentrations (w/w) of: z - 20%, S - 15% and ¡ 
10%. (B) All solutions at 20% (w/w) { - dextran,  - D5,  - D10, U - D25 and V - D40 
Figure 3 - Swelling index profile of dexOx+AAD hydrogels. D25 with feed concentration of 20% and 
D10 and D5 with feed concentration of 30%.  - D25A5;  - D25A10; V - D25A20; Sub-view: -
D10A5; { -D10A10; U - D10A20;  - D5A5; z - D5A10.
Figure 4 - Endothelial cells isolated from rabbit cornea seeded in dexOx+AAD hydrogels, dissolved 
in MEM or PBS, after 72h. A – D5A5, PBS; B – D5A5, MEM; C – D10A10, PBS; D – D10A10, 
MEM; E – D25A10, PBS; F – D25A10, MEM; G – Negative control; H – Positive control. Original 
Magnification X100.
Figure 5 – Cellular activities measured by the MTS assay after 1 day (open bars), 3 days (grey bars) 
and 7 days (black bars). Endothelial cells from rabbit cornea, seeded onto dexOx+AAD hydrogels. 
The materials were either dissolved in PBS or MEM. K+: Positive control; K-: Negative control. All 
error bars represent one standard deviation from six experiments.
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1Tables: Maia et al
Table 1 – Oxidation Degree of several oxidized dextrans calculated by 1H-NMR analysis after 
titration with different carbazates and molecular weight evolution. 
Oxidation degree
Sample
NaIO4a tBCb EtCb
Mnc PDId
Dextran - - - 40.9 1.47
D5 5 2.5 ± 0.3 3.6 ± 0.1 40.8 1.59
D10 10 7.4 ± 0.9 8.6 ± 0.2 37.9 1.61
D25 25 18.9 ± 0.4 22.2 ± 0.7 29.7 2.03
D40 40 -e 33.0 ± 0.8 8.3 3.05
a Theoretical OD, calculated as the molar ratio of sodium periodate per initial glucose unit in 
dextran.
b Calculated by 1H-NMR after titration with tert-butyl carbazate/ethyl carbazate, taking into account 
the ratio between the integral of the peak at G 7.3 ppm and the integral of the anomeric proton at G 4.9 
ppm. Average and standard deviation of 5 independent integrations.
c Number-average molecular weight estimated by SEC
d Polydispersity index corresponding to Mw/Mn
e Precipitation occurred. 
Tables
2Table 2 - Gelation periods estimated for each dexOx with different AAD concentrations.
Gelation period (min) a
dexOx
Feed conc.
% (w/w) 5% AAD 10% AAD 20% AAD
D5 30 66.7 ± 1.4 77.8 ± 5.2 - b
D10 30 14.9 ± 1.7 16.8 ± 0.5 18.8 ± 1.3
D25 20 2.8 ± 0.3 1.6 ± 0.9 1.3 ± 0.2
D40 15 3.7 ± 0.4 2.6 ± 0.1 2.3 ± 0.1
a The gelation period was considered when G’ = G’’; values are mean ± SD (n=4).
b Hydrogel not formed.
